Developer docs
API playgroundTry for free, no card

Search company profiles

ABX GmbH

Full company profile

uuid000kiwu

Namestring
ABX GmbH
Legal namestring
ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH
Websiteurl
abx.de
Company typeenum
Private
Founded yearint
1997
Descriptiontext

ABX GmbH (legal name: ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH) is a Germany-based radiopharmaceutical developer and contract manufacturer headquartered in Radeberg, Saxony. Founded in 1997 with five employees and grown to approximately 400 staff, ABX produces precursor chemicals, peptides, reagent kits, cassettes, and finished diagnostic radiopharmaceuticals for PET (Positron Emission Tomography) and SPECT imaging, including the proprietary prostate-cancer imaging agent Radelumin® (18F-PSMA-1007). The company operates GMP-certified manufacturing facilities with a 10 MeV cyclotron (and a 30 MeV cyclotron under construction), multiple dispensing lines, and full in-house sterility testing, and is the only radiopharmaceutical producer with a complete independent supply chain from precursor/peptide through excipients and sterile disposables.

ABX serves three primary customer segments: (1) pharmaceutical companies developing radiopharmaceutical drugs (for whom ABX provides custom synthesis, GMP manufacturing, and regulatory documentation), (2) nuclear medicine departments and PET centers (purchasing reagent kits, cassettes, and finished products like Radelumin®), and (3) academic and research institutions (for radiotracer development and clinical translation). The company monetizes via direct B2B enterprise sales of products (one-time sale of kits, cassettes, precursors, and finished drug products) and services (custom synthesis, GMP production, regulatory support), with quote-based pricing exclusively to commercial buyers. Distribution combines direct shipping from Radeberg with regional distributors handling Radelumin® in 11 European countries.

Strategically, ABX is wholly owned by Japanese conglomerate Otsuka Holdings since 2007 and operates with operational independence under CEO Dr. Marco Müller (appointed August 2024, succeeding founder Dr. Peter Moll). The company is currently executing a major capacity expansion at its Radeberg site, including a new radiochemistry building and 30 MeV cyclotron, and is a founding member of the nukliD® radiopharmacy cluster in Dresden (established January 2025). ABX also retains economic exposure to Novartis's Pluvicto (177Lu-PSMA-617), which it developed through Phase II before sublicensing to Endocyte (now Novartis).

Short descriptiontext

ABX GmbH is a German GMP manufacturer of radiopharmaceuticals — precursors, reagent kits, cassettes, and finished PET/SPECT drug products — serving pharmaceutical companies, hospitals, and PET centers globally with a fully vertically integrated supply chain.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersRadeberg, Germany
HQ citystring
Radeberg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
PET radiopharmaceuticals, reagent kits cassettes, GMP contract manufacturing, radiopharmaceutical precursors, nuclear medicine diagnostics
Industry2 codes
PRIMARYEUAKAIAE
Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAHABAE
Nuclear Medicine & Molecular Imaging (SPECT/PET)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Radiopharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Radiopharmaceutical Products
TypeOne Time License
Description

Sale of manufactured radiopharmaceuticals including reagent kits & cassettes, small molecules & peptides (600+ different compounds), medicinal products, and accessories (cartridges, columns, evacuated vials).

abx.de
2Custom Synthesis Services
TypeProfessional Services
Description

Custom research, synthesis and manufacturing based on customer needs including lead optimization, precursor development, and radiotracer development.

abx.de
3GMP Production Services
TypeManaged Services
Description

GMP production of radiopharmaceutical drug products from development through early clinical phase to commercial manufacturing, including quality control with in-house sterility testing.

abx.de
4Regulatory Support Services
TypeProfessional Services
Description

Drug Master Files, full CMC documentation, close cooperation with CROs, clinical study setup support, and complete product documentation (SHS, ASMF, DMF).

abx.de
518O Water
TypeHardware Sales
Description

High quality GMP water with DMF (in process) for radiopharmaceutical production.

abx.de
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Pricing details1 tier
1B2B products and services - quote-based pricing
ModelOtherBilling cadencePay-as-you-go
Notes

ABX sells exclusively to entrepreneurs within the meaning of section 14 of the German Civil Code (BGB), meaning only to businesses acting in exercise of their trade, business or profession.

abx.de
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Radelumin®
Description

A radiotracer product ([¹⁸F]PSMA-1007) for PET imaging of prostate cancer, approved in multiple European countries.

abx.de
Core offering1 text field

ABX develops, manufactures, and sells radiopharmaceutical products and services for PET and SPECT imaging, including reagent kits and cassettes, more than 600 small molecules/precursors and peptides, finished medicinal products such as Radelumin® (18F-PSMA-1007), 18O-enriched water, and accessories. It also provides custom synthesis, GMP radiochemistry production, and regulatory support services, leveraging cyclotrons and GMP-certified facilities to serve pharmaceutical companies, hospitals, and PET centers globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 60,000 patients/year treatment capacity with 177Lu-PSMA-617
+3 more records
Product overview1 text field

ABX GmbH is a global radiopharmaceutical company offering a comprehensive portfolio of products and services for PET (Positron Emission Tomography) and SPECT imaging. The core product portfolio consists of Reagent Kits & Cassettes for automated radiopharmaceutical synthesis, Small Molecules & Peptides (600+ compounds including PET/SPECT precursors), Medicinal Products (finished radiopharmaceuticals like Radelumin), 18O Water (target material), and Accessories (disposables and hardware). Notable products include Radelumin (18F-PSMA-1007) for prostate cancer PET diagnostics approved across Europe, and 177Lu-PSMA-617 (Pluvicto) for prostate cancer therapy. The service offering complements the product portfolio with Custom Synthesis (lead optimization, precursor development, radiotracer development), Radiochemistry Services (GMP production with cyclotron facilities, kit/cassette production), and Regulatory Support (DMF, CMC documentation, ASMF). ABX operates a complete independent supply chain from precursor/peptide through excipients and sterile disposables, positioning them as the only service provider with full vertical integration in radiopharmaceutical production.

Product and service8 records
1Reagent Kits & Cassettes
CategoryReagent kits and cassettes
Description

Automated synthesis reagent kits and disposable production cassettes for radiopharmaceutical manufacturing, designed for use with industry-standard synthesis modules (e.g., GE TRACERlab MX, ORA Neptis). Sold to pharmaceutical companies, hospitals, and PET centers.

2Small Molecules & Peptides
CategorySmall molecules and peptides
Description

Portfolio of more than 600 compounds for nuclear medicine, including PET and SPECT precursors, reference standards, and radiopharmaceutical building blocks. Available in multiple quality levels for different regulatory needs.

3Radelumin (18F-PSMA-1007)
CategoryMedicinal products (finished radiopharmaceuticals)
Description

PSMA-targeting PET radiotracer for diagnostic imaging of prostate cancer (primary staging of high-risk patients and suspected recurrence). Approved in 11 European countries including Germany, France, Austria, Belgium, Italy, Luxembourg, Netherlands, Spain, Poland, Portugal, and the UK.

418O Water
CategoryRadiopharmaceutical raw materials
Description

High-quality GMP water enriched with Oxygen-18, used as target material for Fluorine-18 production in PET imaging. Sold with a DMF (in process).

5Accessories
CategoryAccessories and consumables
Description

Hardware and consumables for radiosyntheses, including cartridges, columns, and evacuated vials required for radiopharmaceutical production.

6Custom Synthesis Services
CategoryCustom synthesis services
Description

Custom research, synthesis, and manufacturing services including lead optimization, precursor development, and radiotracer development tailored to customer needs. For pharmaceutical companies and research institutions.

7Radiochemistry Services
CategoryRadiochemistry services (GMP production)
Description

Full-service radiochemistry capabilities including development of radiochemical labeling processes, GMP kit and cassette production, and complete radiopharmaceutical drug product manufacturing with worldwide cold-chain shipment from ABX's Radeberg site. Supports batches from 1–20 vials up to 400 filled vials.

8Regulatory Support Services
CategoryRegulatory support services
Description

Regulatory affairs support including Drug Master Files (DMF), full CMC documentation, ASMF, close cooperation with CROs, and clinical study setup support. Expert in regulatory submissions for reagent kits, cassettes, and PET/SPECT precursors.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ABX developed 177Lu-PSMA-617 through Phase II clinical trials, then sublicensed to Endocyte in 2017 for Phase III. Endocyte was subsequently acquired by Novartis. Together, they led 177Lu-PSMA-617 to market readiness and approval in Europe and the US in 2022 (marketed as Pluvicto by Novartis).

Strategic tierCoreTypeStrategic or Co-development Partner
Description

DKFZ commissioned ABX in 2014 to develop 177Lu-PSMA-617, granting worldwide exclusive license. DKFZ also licensed 18F-PSMA-1007 to ABX in 2016. ABX conducted clinical studies and obtained regulatory approvals.

3Prof. Dr. Frederik L. Giesel (University Hospital Düsseldorf)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Development partner for Radelumin® (18F-PSMA-1007), providing clinical expertise as Director of Clinic for Nuclear Medicine at University Hospital Düsseldorf.

abx.de
4Prof. Dr. Klaus Kopka (Helmholtz-Zentrum Dresden-Rossendorf)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Development partner for Radelumin®, providing research expertise as Director of Institute of Radiopharmaceutical Cancer Research at Helmholtz-Zentrum Dresden-Rossendorf and formerly head of Radiopharmaceutical Chemistry at DKFZ.

abx.de
5nukliD® (Radiopharmacy Cluster Dresden)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

ABX is a founding member of nukliD®, the Radiopharmacy Cluster Dresden, established January 2025 to strengthen the radiopharmaceutical ecosystem in the Dresden region.

abx.de
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Curium is one of the world's largest nuclear medicine companies, supplying PET and SPECT radiopharmaceuticals globally. Highly comparable to ABX as a direct competitor in PET/SPECT tracer manufacturing and distribution to hospitals/PET centers.

TypeDirect peer
Description

PETNET Solutions operates a global network of PET radiopharmaceutical manufacturing and distribution sites. Directly comparable to ABX as a PET tracer producer serving hospitals and imaging centers with FDG and other diagnostic tracers.

TypeBroad incumbent
Description

GE Healthcare produces and distributes PET radiopharmaceuticals including FDG and operates the TRACERlab synthesis platform compatible with ABX cassettes. Direct competitor in PET tracer manufacturing and adjacent in synthesis hardware.

TypeDirect peer
Description

Lantheus is a radiopharmaceutical-focused company developing and commercializing diagnostic and therapeutic agents. Comparable to ABX in radiopharma development focus, with overlapping PSMA and theranostics interests.

TypeDirect peer
Description

Telix develops and commercializes radiopharmaceuticals for cancer diagnosis and therapy, including PSMA-targeting agents. Comparable to ABX in the theranostics/PSMA competitive landscape.

TypeBroad incumbent
Description

Bracco Imaging is a global diagnostic imaging company with significant radiopharmaceutical and contrast media operations. Comparable to ABX as a broader diagnostic imaging agent manufacturer with overlapping customer base in nuclear medicine.

TypeBroad incumbent
Description

Cardinal Health operates one of the largest radiopharmacy networks in the US, distributing PET and SPECT products. Comparable to ABX as a radiopharma distribution and compounding competitor, particularly for US-market access.

TypeBroad incumbent
Description

Bayer has a radiopharmaceuticals business developed from the Algeta acquisition, focused on therapeutic radioligands. Comparable to ABX in the therapeutic radiopharma space with Xofigo heritage and ongoing pipeline development.

TypeOthers
Description

Novartis commercializes Pluvicto (177Lu-PSMA-617), originally developed and sublicensed from ABX. Highly relevant as ABX's key downstream partner and as a customer of ABX's contract manufacturing/precursor services.

TypeEmerging player
Description

IsoTherapeutics is a contract manufacturer of radiopharmaceuticals and radioisotopes for clinical and commercial use. Comparable to ABX as a smaller-scale radiopharma CDMO with overlapping custom synthesis and GMP production services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ABX GmbH

Radiopharmaceuticalsabx.de

ABX GmbH is a German GMP manufacturer of radiopharmaceuticals — precursors, reagent kits, cassettes, and finished PET/SPECT drug products — serving pharmaceutical companies, hospitals, and PET centers globally with a fully vertically integrated supply chain.

What ABX GmbH does

ABX GmbH (legal name: ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH) is a Germany-based radiopharmaceutical developer and contract manufacturer headquartered in Radeberg, Saxony. Founded in 1997 with five employees and grown to approximately 400 staff, ABX produces precursor chemicals, peptides, reagent kits, cassettes, and finished diagnostic radiopharmaceuticals for PET (Positron Emission Tomography) and SPECT imaging, including the proprietary prostate-cancer imaging agent Radelumin® (18F-PSMA-1007). The company operates GMP-certified manufacturing facilities with a 10 MeV cyclotron (and a 30 MeV cyclotron under construction), multiple dispensing lines, and full in-house sterility testing, and is the only radiopharmaceutical producer with a complete independent supply chain from precursor/peptide through excipients and sterile disposables.

ABX serves three primary customer segments: (1) pharmaceutical companies developing radiopharmaceutical drugs (for whom ABX provides custom synthesis, GMP manufacturing, and regulatory documentation), (2) nuclear medicine departments and PET centers (purchasing reagent kits, cassettes, and finished products like Radelumin®), and (3) academic and research institutions (for radiotracer development and clinical translation). The company monetizes via direct B2B enterprise sales of products (one-time sale of kits, cassettes, precursors, and finished drug products) and services (custom synthesis, GMP production, regulatory support), with quote-based pricing exclusively to commercial buyers. Distribution combines direct shipping from Radeberg with regional distributors handling Radelumin® in 11 European countries.

Strategically, ABX is wholly owned by Japanese conglomerate Otsuka Holdings since 2007 and operates with operational independence under CEO Dr. Marco Müller (appointed August 2024, succeeding founder Dr. Peter Moll). The company is currently executing a major capacity expansion at its Radeberg site, including a new radiochemistry building and 30 MeV cyclotron, and is a founding member of the nukliD® radiopharmacy cluster in Dresden (established January 2025). ABX also retains economic exposure to Novartis's Pluvicto (177Lu-PSMA-617), which it developed through Phase II before sublicensing to Endocyte (now Novartis).

ABX GmbH firmographics

Firmographics
Name
ABX GmbH
Legal name
ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH
Website
https://abx.de
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
101–250 employees
Short description
ABX GmbH is a German GMP manufacturer of radiopharmaceuticals — precursors, reagent kits, cassettes, and finished PET/SPECT drug products — serving pharmaceutical companies, hospitals, and PET centers globally with a fully vertically integrated supply chain.
Ownership category
akta.pro rank

ABX GmbH industry classification

Industry
Product category
Radiopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYEUAKAIAE
Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAHABAE
Nuclear Medicine & Molecular Imaging (SPECT/PET)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

Keywords

  • PET radiopharmaceuticals
  • Reagent kits cassettes
  • GMP contract manufacturing
  • Radiopharmaceutical precursors
  • Nuclear medicine diagnostics

Where ABX GmbH is headquartered

Location

Headquarters

HQ city
Radeberg
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

ABX GmbH business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Radiopharmaceutical Products: Sale of manufactured radiopharmaceuticals including reagent kits & cassettes, small molecules & peptides (600+ different compounds), medicinal products, and accessories (cartridges, columns, evacuated vials).
  2. Custom Synthesis Services: Custom research, synthesis and manufacturing based on customer needs including lead optimization, precursor development, and radiotracer development.
  3. GMP Production Services: GMP production of radiopharmaceutical drug products from development through early clinical phase to commercial manufacturing, including quality control with in-house sterility testing.
  4. Regulatory Support Services: Drug Master Files, full CMC documentation, close cooperation with CROs, clinical study setup support, and complete product documentation (SHS, ASMF, DMF).
  5. 18O Water: High quality GMP water with DMF (in process) for radiopharmaceutical production.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goB2B products and services - quote-based pricing

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

ABX GmbH product offering

Product offering

Core offering

ABX develops, manufactures, and sells radiopharmaceutical products and services for PET and SPECT imaging, including reagent kits and cassettes, more than 600 small molecules/precursors and peptides, finished medicinal products such as Radelumin® (18F-PSMA-1007), 18O-enriched water, and accessories. It also provides custom synthesis, GMP radiochemistry production, and regulatory support services, leveraging cyclotrons and GMP-certified facilities to serve pharmaceutical companies, hospitals, and PET centers globally.

Product overview

ABX GmbH is a global radiopharmaceutical company offering a comprehensive portfolio of products and services for PET (Positron Emission Tomography) and SPECT imaging. The core product portfolio consists of Reagent Kits & Cassettes for automated radiopharmaceutical synthesis, Small Molecules & Peptides (600+ compounds including PET/SPECT precursors), Medicinal Products (finished radiopharmaceuticals like Radelumin), 18O Water (target material), and Accessories (disposables and hardware). Notable products include Radelumin (18F-PSMA-1007) for prostate cancer PET diagnostics approved across Europe, and 177Lu-PSMA-617 (Pluvicto) for prostate cancer therapy. The service offering complements the product portfolio with Custom Synthesis (lead optimization, precursor development, radiotracer development), Radiochemistry Services (GMP production with cyclotron facilities, kit/cassette production), and Regulatory Support (DMF, CMC documentation, ASMF). ABX operates a complete independent supply chain from precursor/peptide through excipients and sterile disposables, positioning them as the only service provider with full vertical integration in radiopharmaceutical production.

Differentiator

Problem solved

Functional benefit

Brands

  • Radelumin®: A radiotracer product ([¹⁸F]PSMA-1007) for PET imaging of prostate cancer, approved in multiple European countries.

Products and services

  • Reagent Kits & Cassettes Automated synthesis reagent kits and disposable production cassettes for radiopharmaceutical manufacturing, designed for use with industry-standard synthesis modules (e.g., GE TRACERlab MX, ORA Neptis). Sold to pharmaceutical companies, hospitals, and PET centers.
  • Small Molecules & Peptides Portfolio of more than 600 compounds for nuclear medicine, including PET and SPECT precursors, reference standards, and radiopharmaceutical building blocks. Available in multiple quality levels for different regulatory needs.
  • Radelumin (18F-PSMA-1007) PSMA-targeting PET radiotracer for diagnostic imaging of prostate cancer (primary staging of high-risk patients and suspected recurrence). Approved in 11 European countries including Germany, France, Austria, Belgium, Italy, Luxembourg, Netherlands, Spain, Poland, Portugal, and the UK.
  • 18O Water High-quality GMP water enriched with Oxygen-18, used as target material for Fluorine-18 production in PET imaging. Sold with a DMF (in process).
  • Accessories Hardware and consumables for radiosyntheses, including cartridges, columns, and evacuated vials required for radiopharmaceutical production.
  • Custom Synthesis Services Custom research, synthesis, and manufacturing services including lead optimization, precursor development, and radiotracer development tailored to customer needs. For pharmaceutical companies and research institutions.
  • Radiochemistry Services Full-service radiochemistry capabilities including development of radiochemical labeling processes, GMP kit and cassette production, and complete radiopharmaceutical drug product manufacturing with worldwide cold-chain shipment from ABX's Radeberg site. Supports batches from 1–20 vials up to 400 filled vials.
  • Regulatory Support Services Regulatory affairs support including Drug Master Files (DMF), full CMC documentation, ASMF, close cooperation with CROs, and clinical study setup support. Expert in regulatory submissions for reagent kits, cassettes, and PET/SPECT precursors.

Quantifiable outcome

  • 60,000 patients/year treatment capacity with 177Lu-PSMA-617
  • +3 more outcomes

Companies that use ABX GmbH

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

ABX GmbH technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature4 records

ABX GmbH partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Novartis (formerly Endocyte)coreStrategic or Co-development PartnerABX developed 177Lu-PSMA-617 through Phase II clinical trials, then sublicensed to Endocyte in 2017 for Phase III. Endocyte was subsequently acquired by Novartis. Together, they led 177Lu-PSMA-617 to market readiness and approval in Europe and the US in 2022 (marketed as Pluvicto by Novartis).
  • German Cancer Research Centre (DKFZ)coreStrategic or Co-development PartnerDKFZ commissioned ABX in 2014 to develop 177Lu-PSMA-617, granting worldwide exclusive license. DKFZ also licensed 18F-PSMA-1007 to ABX in 2016. ABX conducted clinical studies and obtained regulatory approvals.
  • Prof. Dr. Frederik L. Giesel (University Hospital Düsseldorf)minorStrategic or Co-development PartnerDevelopment partner for Radelumin® (18F-PSMA-1007), providing clinical expertise as Director of Clinic for Nuclear Medicine at University Hospital Düsseldorf.
  • Prof. Dr. Klaus Kopka (Helmholtz-Zentrum Dresden-Rossendorf)minorStrategic or Co-development PartnerDevelopment partner for Radelumin®, providing research expertise as Director of Institute of Radiopharmaceutical Cancer Research at Helmholtz-Zentrum Dresden-Rossendorf and formerly head of Radiopharmaceutical Chemistry at DKFZ.
  • nukliD® (Radiopharmacy Cluster Dresden)minorStrategic or Co-development PartnerABX is a founding member of nukliD®, the Radiopharmacy Cluster Dresden, established January 2025 to strengthen the radiopharmaceutical ecosystem in the Dresden region.

Scale indicators12 records

Recent moves9 records

Expansion highlights7 records

ABX GmbH competitors and assessment

Company assessment

Broad incumbents

  • Curium: Curium is one of the world's largest nuclear medicine companies, supplying PET and SPECT radiopharmaceuticals globally. Highly comparable to ABX as a direct competitor in PET/SPECT tracer manufacturing and distribution to hospitals/PET centers.
  • GE Healthcare (Pharmaceutical Diagnostics): GE Healthcare produces and distributes PET radiopharmaceuticals including FDG and operates the TRACERlab synthesis platform compatible with ABX cassettes. Direct competitor in PET tracer manufacturing and adjacent in synthesis hardware.
  • Bracco Imaging: Bracco Imaging is a global diagnostic imaging company with significant radiopharmaceutical and contrast media operations. Comparable to ABX as a broader diagnostic imaging agent manufacturer with overlapping customer base in nuclear medicine.
  • Cardinal Health (Nuclear & Precision Health Solutions): Cardinal Health operates one of the largest radiopharmacy networks in the US, distributing PET and SPECT products. Comparable to ABX as a radiopharma distribution and compounding competitor, particularly for US-market access.
  • Bayer (radiopharmaceuticals): Bayer has a radiopharmaceuticals business developed from the Algeta acquisition, focused on therapeutic radioligands. Comparable to ABX in the therapeutic radiopharma space with Xofigo heritage and ongoing pipeline development.

Direct peers

  • PETNET Solutions (Siemens Healthineers): PETNET Solutions operates a global network of PET radiopharmaceutical manufacturing and distribution sites. Directly comparable to ABX as a PET tracer producer serving hospitals and imaging centers with FDG and other diagnostic tracers.
  • Lantheus Holdings: Lantheus is a radiopharmaceutical-focused company developing and commercializing diagnostic and therapeutic agents. Comparable to ABX in radiopharma development focus, with overlapping PSMA and theranostics interests.
  • Telix Pharmaceuticals: Telix develops and commercializes radiopharmaceuticals for cancer diagnosis and therapy, including PSMA-targeting agents. Comparable to ABX in the theranostics/PSMA competitive landscape.

Others

  • Novartis (Pluvicto franchise): Novartis commercializes Pluvicto (177Lu-PSMA-617), originally developed and sublicensed from ABX. Highly relevant as ABX's key downstream partner and as a customer of ABX's contract manufacturing/precursor services.

Emerging players

  • IsoTherapeutics Group: IsoTherapeutics is a contract manufacturer of radiopharmaceuticals and radioisotopes for clinical and commercial use. Comparable to ABX as a smaller-scale radiopharma CDMO with overlapping custom synthesis and GMP production services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

ABX GmbH social profiles

Digital presence

ABX GmbH compliance and trust

Trust signal

Compliance4 records

ABX GmbH financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ABX GmbH leadership team

Management profile

Number of profiles

Profiles3 records

ABX GmbH funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ABX GmbH M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ABX GmbH

What does ABX GmbH do?

ABX develops, manufactures, and sells radiopharmaceutical products and services for PET and SPECT imaging, including reagent kits and cassettes, more than 600 small molecules/precursors and peptides, finished medicinal products such as Radelumin® (18F-PSMA-1007), 18O-enriched water, and accessories. It also provides custom synthesis, GMP radiochemistry production, and regulatory support services, leveraging cyclotrons and GMP-certified facilities to serve pharmaceutical companies, hospitals, and PET centers globally.

Is ABX GmbH a public or private company?

ABX GmbH is a private company. It is classified as corporate owned and is currently operating.

When was ABX GmbH founded?

ABX GmbH was founded in 1997. It employs 101 to 250 people.

Where is ABX GmbH based?

ABX GmbH is headquartered in Radeberg, Germany, in the Europe region.

How does ABX GmbH make money?

Five revenue lines are on record. Radiopharmaceutical Products are the primary driver. The others are custom Synthesis Services, GMP Production Services, regulatory Support Services and 18O Water.

Who are ABX GmbH's main competitors?

Broad incumbents on record are Curium, GE Healthcare (Pharmaceutical Diagnostics), Bracco Imaging, Cardinal Health (Nuclear & Precision Health Solutions) and Bayer (radiopharmaceuticals). Direct peers are PETNET Solutions (Siemens Healthineers), Lantheus Holdings and Telix Pharmaceuticals. Novartis (Pluvicto franchise) is listed as an others. IsoTherapeutics Group is listed as an emerging player.

Does ABX GmbH have an API?

No public API is recorded for ABX GmbH.

What industry is ABX GmbH in?

ABX GmbH's product category is Radiopharmaceuticals. Its primary akta.pro industry code is EUAKAIAE, Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain), with a secondary code of HLAHABAE, Nuclear Medicine & Molecular Imaging (SPECT/PET). Its NAICS code is 325412 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals